PROPOSE: To explore the value of unmeasurable enhancement pattern of residual cavity in predicting survival at early stage after gross-total resection in high-grade glioma (HGG) patients. METHODS: This retrospective study enrolled consecutive 51 HGG patients with unmeasurable enhancement who underwent gross-total resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. We evaluated the enhancement patterns of residual cavity on contrast-T1WI made within 1 month after tumor resection (20 ± 3 days). The survival state of different enhancement was compared. RESULTS: Thin-linear, thick-linear and nodular enhancement were observed in 22 patients (43%), 10 patients (20%), and 19 patients (37%), respectively. The progression-free survival of patients with thin-linear (487, 151-887 days) was longer than those patients with thick-linear (277, 133-573 days), and nodular enhancement (210, 120-765 days) (P = 0.002). The overall survival of patients with thin-linear (774, 457-1343 days) was longer than those with thick-linear (462, 320-678 days), and nodular enhancement (326, 234-1393 days) (P = 0.002). There was no significant difference of orthogonal value between thick-linear and nodular enhancement (0.854), neither between grade III and IV with same enhancement patterns (P = 0.540, P = 0.720). CONCLUSIONS: The unmeasurable enhancement patterns in HGG patients within 1 month after gross-total resection, which might be better than the grade of tumor, holds a potential marker in survival state.
PROPOSE: To explore the value of unmeasurable enhancement pattern of residual cavity in predicting survival at early stage after gross-total resection in high-grade glioma (HGG) patients. METHODS: This retrospective study enrolled consecutive 51 HGG patients with unmeasurable enhancement who underwent gross-total resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. We evaluated the enhancement patterns of residual cavity on contrast-T1WI made within 1 month after tumor resection (20 ± 3 days). The survival state of different enhancement was compared. RESULTS: Thin-linear, thick-linear and nodular enhancement were observed in 22 patients (43%), 10 patients (20%), and 19 patients (37%), respectively. The progression-free survival of patients with thin-linear (487, 151-887 days) was longer than those patients with thick-linear (277, 133-573 days), and nodular enhancement (210, 120-765 days) (P = 0.002). The overall survival of patients with thin-linear (774, 457-1343 days) was longer than those with thick-linear (462, 320-678 days), and nodular enhancement (326, 234-1393 days) (P = 0.002). There was no significant difference of orthogonal value between thick-linear and nodular enhancement (0.854), neither between grade III and IV with same enhancement patterns (P = 0.540, P = 0.720). CONCLUSIONS: The unmeasurable enhancement patterns in HGG patients within 1 month after gross-total resection, which might be better than the grade of tumor, holds a potential marker in survival state.
Entities:
Keywords:
Chemoradiotherapy; Enhancement; Glioma; Magnetic resonance imaging; Outcome
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: Jennifer L Clarke; Annette M Molinaro; Joanna J Phillips; Nicholas A Butowski; Susan M Chang; Arie Perry; Joseph F Costello; Ashley A DeSilva; Jane E Rabbitt; Michael D Prados Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: Cecelia Elizabeth Gzell; Helen R Wheeler; Philip McCloud; Marina Kastelan; Michael Back Journal: J Neurooncol Date: 2016-02-15 Impact factor: 4.130